Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Amarin Corporation

Share:
Related AMRN
Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings
Watch These 8 Huge Call Purchases In Wednesday Trade

In a report published Friday, Canaccord Genuity reiterated its Buy rating on Amarin Corporation (NASDAQ: AMRN), but lowered its price target from $26.00 to $19.00.

Canaccord Genuity noted, “Reiterate BUY, lowering target to $19; maintain positive view on Vascepa commercial, partnering potential while acknowledging increased commercial risk. We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $19 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”

Amarin Corporation closed on Thursday at $11.95.

Latest Ratings for AMRN

DateFirmActionFromTo
Oct 2016CitigroupInitiates Coverage OnBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!